BD to Announce Financial Results for its First Quarter of Fiscal 2026
BD (NYSE: BDX) will host an audio webcast at 8:00 a.m. ET on Monday, February 9, 2026 to discuss financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) and to provide an update on operations and strategy.
Rhea-AI Summary
BD (NYSE: BDX) will host an audio webcast at 8:00 a.m. ET on Monday, February 9, 2026 to discuss financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) and to provide an update on operations and strategy. Prior to the call, the company will issue a news release and presentation materials including summary financial information.
The live audio webcast and subsequent replay will be available at www.bd.com/investors.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BDX
On Jan 27, the day this news came out, BDX closed 0.01% below the previous close.
Data tracked by StockTitan Argus for the Jan 27 session.
Key Figures
- Webcast time
- 8 a.m. ET
- Earnings call on February 9, 2026
- Quarter end date
- December 31, 2025
- Fiscal Q1 2026 reporting period
- Fiscal period
- First quarter fiscal 2026
- Results to be discussed on webcast
Historical Context
-
Global launch of BD Research Cloud 7.0 with AI panel design tools.
-
Expanded Ypsomed partnership for 5.5 mL Neopak XtraFlow syringe platform.
-
FDA 510(k) clearance for EnCor EnCompass breast biopsy system.
-
Appointment of Shawn Bevec as senior vice president of investor relations.
-
$110 million investment to expand U.S. Neopak syringe production capacity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Matt Marcus | Shawn Bevec |
VP, Public Relations | SVP, Investor Relations |
View original content:https://www.prnewswire.com/news-releases/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-2026-302671314.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.